A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Abstract The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and futur...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-12-01
|
| Series: | Oncology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40487-024-00315-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251622200901632 |
|---|---|
| author | Melissa L. Johnson Jessica J. Lin Adrienne Boire Melin J. Khandekar Helena A. Yu |
| author_facet | Melissa L. Johnson Jessica J. Lin Adrienne Boire Melin J. Khandekar Helena A. Yu |
| author_sort | Melissa L. Johnson |
| collection | DOAJ |
| description | Abstract The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and future treatments for brain metastases that develop in patients with EGFR-mutated NSCLC. The panel discusses surveillance and management of patients with brain metastases, different types of currently used treatments, and recent data on the intracranial efficacy of antibody–drug conjugates (ADCs). The panel also discusses current and future studies of ADCs in patients with EGFR-mutated NSCLC with brain metastases. This podcast discussion, among four oncologists (two thoracic oncologists, one radiation oncologist, and one neurologist/neuro-oncologist), is for healthcare professionals (HCPs) at community practices and research institutions. |
| format | Article |
| id | doaj-art-dcc47ee2ddf34189832fc4b3080989f1 |
| institution | OA Journals |
| issn | 2366-1070 2366-1089 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Oncology and Therapy |
| spelling | doaj-art-dcc47ee2ddf34189832fc4b3080989f12025-08-20T01:57:51ZengAdis, Springer HealthcareOncology and Therapy2366-10702366-10892024-12-01131173010.1007/s40487-024-00315-1A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain MetastasesMelissa L. Johnson0Jessica J. Lin1Adrienne Boire2Melin J. Khandekar3Helena A. Yu4Sarah Cannon Research InstituteMassachusetts General HospitalMemorial Sloan Kettering Cancer CenterMassachusetts General HospitalMemorial Sloan Kettering Cancer CenterAbstract The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and future treatments for brain metastases that develop in patients with EGFR-mutated NSCLC. The panel discusses surveillance and management of patients with brain metastases, different types of currently used treatments, and recent data on the intracranial efficacy of antibody–drug conjugates (ADCs). The panel also discusses current and future studies of ADCs in patients with EGFR-mutated NSCLC with brain metastases. This podcast discussion, among four oncologists (two thoracic oncologists, one radiation oncologist, and one neurologist/neuro-oncologist), is for healthcare professionals (HCPs) at community practices and research institutions.https://doi.org/10.1007/s40487-024-00315-1Brain metastasesNon-small cell lung cancerEGFR-mutatedADCAntibody–drug conjugate |
| spellingShingle | Melissa L. Johnson Jessica J. Lin Adrienne Boire Melin J. Khandekar Helena A. Yu A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases Oncology and Therapy Brain metastases Non-small cell lung cancer EGFR-mutated ADC Antibody–drug conjugate |
| title | A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases |
| title_full | A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases |
| title_fullStr | A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases |
| title_full_unstemmed | A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases |
| title_short | A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases |
| title_sort | podcast discussion on the intracranial efficacy of antibody drug conjugates in patients with egfr mutated nsclc with brain metastases |
| topic | Brain metastases Non-small cell lung cancer EGFR-mutated ADC Antibody–drug conjugate |
| url | https://doi.org/10.1007/s40487-024-00315-1 |
| work_keys_str_mv | AT melissaljohnson apodcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT jessicajlin apodcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT adrienneboire apodcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT melinjkhandekar apodcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT helenaayu apodcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT melissaljohnson podcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT jessicajlin podcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT adrienneboire podcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT melinjkhandekar podcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases AT helenaayu podcastdiscussionontheintracranialefficacyofantibodydrugconjugatesinpatientswithegfrmutatednsclcwithbrainmetastases |